Breast Cancer Clinical Trials in Pittsburgh

Showing 221-240 of 717 trials

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

OncologyMelanomaOvarian Cancer+14 more

Palleon Pharmaceuticals, Inc.69 participantsStarted Feb 2022

La Jolla, California, United States • Los Angeles, California, United States • Stanford, California, United States +10 more locations

COMPLETEDPhase 2< 1 mile

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

NCT01149083

This phase II trial studies how well veliparib with or without carboplatin works in treating patients with stage III or IV breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether veliparib is more effective with or without carboplatin in treating breast cancer.

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Breast Carcinoma+2 more

National Cancer Institute (NCI)77 participantsStarted Jun 2010

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +20 more locations

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Breast Cancer Trials in Other Cities

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

A Study of ADRX-0706 in Select Advanced Solid Tumors

MGC018 With or Without MGA012 in Advanced Solid Tumors

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

MarginProbe 2.0 Data Collection Protocol

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Other Conditions in Pittsburgh